Comparison Of Apidra To Regular Insulin In Hospitalized Patients (apidra)
The purpose of this study is to compare Apidra (a rapid acting insulin analogue) with Regular insulin (fast acting) in addition to the use of long acting insulin Glargine in hospitalized patients in terms of efficacy and safety in blood glucose control and frequency of low blood glucose. Blood glucose control along with incidence and rate of low blood glucose during the hospitalization shall be of primary interest; length of hospital stay comparing the short acting insulin used shall be the secondary interest. OBJECTIVES: To compare the rapid acting insulin analogue Apidra with regular insulin in addition to insulin Glargine in hospitalized patients in terms of efficacy and safety, namely Glycemic control and frequency of hypoglycemia. Glycemic control, and incidence and rate of hypoglycemia during the hospitalization shall be the primary endpoints; length of hospital stay according to the short acting insulin used shall be the secondary endpoint. RESEARCH DESIGN: Randomized, prospective study. METHODS: Inpatient single center study, planning to enroll 600 patients with type II diabetes admitted to medical or surgical non-ICU service for three days or longer. Subjects will be randomized to Apidra or regular insulin in a 1:1 fashion. Insulin Glargine will be given once a day for basal insulin in all subjects. An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hypergl Continue reading >>
Test Driving Insulin
How many insulins have you tried? If you're like most people, you only switch to something new when a better generation comes out, such as when Regular upgraded to Humalog or when NPH upgraded to Lantus. But when it comes to comparing insulin in the same family, say Humalog versus Novolog or Lantus versus Levemir, most of us only try something new when something goes very wrong, such as burning at the injection site. Yech... But what really differentiates them anyway? On the outside, there aren't many distinct differences between Humalog, Novolog and Apidra. They are all rapid-acting insulin designed to enhance upon the classic Regular. They have a quick onset (between 10 and 15 minutes) and are generally are out of your system in a couple of hours. But if you ask an individual, "Which insulin do you use?" you'll get a variety of answers and a variety of reasons. When Apidra came to market in 2004, it claimed the title of speed champion. While Humalog was fast, and Novolog was faster, Apidra was the fastest, according to manufacturer Sanofi-Aventis. Actually, there is no scientific evidence that there are any major difference between the different brands of rapid-acting insulin. "I have seen zero reliable research (ie, not conducted by an insulin company) showing any difference in action times," says expert John Walsh, PA, CDE, and author of Pumping Insulin. But many people — including many Apidra users like myself! — still claim otherwise. We surveyed the folks at TuDiabetes to get their impressions of how the different insulins have affected their blood sugar, and several people responded with interesting feedback about the new kid on the block, Apidra. Linzie, a type 1, switched to Apidra when she went on her insulin pump. "Apidra works really quick compared to t Continue reading >>
Insulin Glulisine
Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.[1] It was developed by Sanofi-Aventis and is sold under the trade name Apidra.[2] When injected subcutaneously, it appears in the blood earlier than human insulin.[3] When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal.[4] Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional.[5] [edit] External links[edit] Apidra Homepage Continue reading >>
Apidra (insulin Glulisine)
Apidra is the brand name for human analog insulin glulisine. It is used to help treat diabetes by lowering levels of glucose in the blood. It can be used by both adults and children over four years old, with type 1 or type 2 diabetes. Apidra is one of the insulins in the fast-acting class (also called rapid-acting). This means that the onset of Apidra is about 15 minutes from the time you take it. By contrast, insulins from the short-acting class take effect within 30 to 60 minutes. Long-acting insulins take two to four hours to begin working. Apidra was developed by Sanofi-Aventis, who also produces the most popular type of long-acting insulin, Lantus. The two (Apidra and Lantus) can be taken in conjunction, and in fact, you should be on a longer-acting insulin if you’re taking Apidra for mealtimes. Apidra will only work for two to four hours total, so you need another type of insulin to cover you between mealtimes and overnight. How Do I Take Apidra? Apidra is available in several ways. You can inject it with a needle subcutaneously, you can put it in an insulin infusion pump, you can get it in pen form, and it can also be administered via an IV, if you’re in the hospital. If you’re using the pre-filled pens, it’s important to note that your pens should be kept refrigerated until you’re ready to start using one. Once you start using a pen, it’s good for 28 days unrefrigerated, but only if it’s kept at a room temperature no warmer than 77 degrees Fahrenheit. When Should I Take Apidra? Apidra is known as a mealtime insulin and was designed to only be taken when you’re eating, in order to manage mealtime spikes as well as to correct high blood sugar in people with type 1 diabetes or those who have been instructed to do so. It’s been approved to be injec Continue reading >>
What Are The Possible Side Effects Of Insulin Glulisine (apidra, Apidra Opticlik Cartridge, Apidra Solostar Pen)?
APIDRA (insulin glulisine [rDNA origin]) Solution for Injection DESCRIPTION APIDRA® (insulin glulisine [rDNA origin] injection) is a rapid-acting human insulin analog used to lower blood glucose. Insulin glulisine is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12). Insulin glulisine differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. Chemically, insulin glulisine is 3B-lysine29B-glutamic acid-human insulin, has the empirical formula C258H384N64O78S6 and a molecular weight of 5823 and has the following structural formula: APIDRA is a sterile, aqueous, clear, and colorless solution. Each milliliter of APIDRA contains 100 units (3.49 mg) insulin glulisine, 3.15 mg metacresol, 6 mg tromethamine, 5 mg sodium chloride, 0.01 mg polysorbate 20, and water for injection. APIDRA has a pH of approximately 7.3. The pH is adjusted by addition of aqueous solutions of hydrochloric acid and/or sodium hydroxide. font size A A A Type 2 diabetes: See Diabetes, type 2. Source: MedTerms™ Medical Dictionary Continue reading >>
Apidra (insulin Glulisine) Dosing, Indications, Interactions, Adverse Effects, And More
Indicated to improve glycemic control in adults and children with diabetes mellitus Equipotent to regular human insulin (ie, elicits same glucose lowering effects on unit per unit basis) when administered IV Insulin glulisine has a more rapid onset of action and a shorter duration of action than regular human insulin Dosage must be individualized; blood glucose monitoring is essential in all patients receiving insulin therapy Total daily insulin requirement may vary and is usually between 0.5-1 unit/kg/day Insulin requirements may be altered during stress, major illness, or with changes in exercise, meal patterns, or coadministered drugs Administer within 15 minutes before a meal or within 20 minutes after starting a meal When administered by SC injection, insulin glulisine should generally be used in regimens with an intermediate- or long-acting insulin Administered by SC injection in the abdominal wall, thigh, or upper arm Injection sites should be rotated within the same region (abdomen, thigh or upper arm) from one injection to the next to reduce the risk of lipodystrophy May be administered by continuous SC infusion in the abdominal wall Do not dilute or mix with any other insulin Infusion sites should be rotated within the same region to reduce the risk of lipodystrophy Insulin in the reservoir must be changed at least q48hr Do not expose to temeratures >98.6 F (37 C) Initial programming of the external insulin infusion pump should be based on the total daily insulin dose of the previous regimen Malfunction of the insulin pump or infusion set, or handling errors or insulin degradation can rapidly lead to hyperglycemia, ketosis and diabetic ketoacidosis See prescribing information for compatible insulin pumps May be administered IV while under medical supervision Continue reading >>
The Role Of Insulin Glulisine To Improve Glycemic Control In Children With Diabetes Mellitus
The role of insulin glulisine to improve glycemic control in children with diabetes mellitus Anna Lih , Emily Hibbert , Tang Wong , Christian M Girgis , Nidhi Garg , and John N Carter Department of Endocrinology and Metabolism, Concord Hospital, NSW, Australia; University of Sydney, Camperdown, NSW, Australia Correspondence: John Carter, Clinical Professor of Medicine, Department of Endocrinology and Metabolism, Level 6, Concord Hospital Medical Center, Concord Hospital, Concord, NSW, Australia, Tel +61 02 94773701, Fax +61 02 9482 2036, Email ua.ten.dnopgib@retracj Author information Copyright and License information Disclaimer Copyright 2010 Lih et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. This article has been cited by other articles in PMC. Glulisine (Apidra) is a rapid-acting human insulin analog approved for use in children with diabetes mellitus 4 years of age. Management of children with type 1 diabetes has seen a shift in favor of mimicking normal physiological insulin responses with multiple daily injections or continuous subcutaneous insulin infusions (CSII). Few studies have compared the rapid-acting insulin analogs in this population but limited data indicate that glulisine is as effective as lispro when used in a basalbolus regimen. This review appraises the current available studies and reviews on insulin glulisine in children. An extensive keyword search of insulin glulisine, insulin analogs, and Apidra in the pediatric population was performed. These studies have suggested that glulisine is safe, well tolerated, and is an effective option in the diabetes armamentarium. Further studies are needed to determine its safety for Continue reading >>
- The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus
- Association of Glycemic Variability in Type 1 Diabetes With Progression of Microvascular Outcomes in the Diabetes Control and Complications Trial
- Children's Diabetes Foundation The 2017 Carousel Ball - Children's Diabetes Foundation
Important Safety Information For Apidra (insulin Glulisine [rdna Origin] Injection) Solostar
Vs RHI and lispro: Onset of action5,6,7,a The action profile of Apidra was not affected by skin thickness or BMI2 For the purposes of this trial, references to lispro refer to Humalog manufactured by Eli Lilly & Co. Becker study: The pharmacokinetics and pharmacodynamics of Apidra, RHI, and lispro were examined in a single-dose, randomized, double-blind, 3-way crossover euglycemic clamp study of 18 obese, nondiabetic subjects. An SC injection of 0.3 U/kg of each insulin was administered in the abdominal area in predetermined sequences. The washout periods between the clamp procedures for each insulin were at least 7 days. After administration, infusion of a 20% glucose solution started when BG fell below 10% of mean baseline level. PD parameters were derived from the individual glucose infusion rate profiles.2,5 Point estimate vs Apidra (95% CI): RHI: -36 min (-96; -20 min). Vs aspart : During the first hour following a meal3 In a PK/PD study, Apidra was associated with lower BG levels during the first hour after a standard meal in insulin naive, obese patients with T2DM3 For the purposes of this trial, references to aspart refer to Novalog manufactured by Novo Nordisk Inc. Bolli study: A multinational, randomized, double-blind, two-way crossover trial to compare the PK and PD properties of SC Apidra and insulin aspart in 30 insulin-naive, obese, T2DM subjects. Patients fasted overnight and received a 0.2 U/kg SC dose of either Apidra or aspart 2 minutes before starting a standardized meal. The procedure was repeated with the alternative insulin after a 7-day washout period. The primary objective was to assess the PD effect (as measured by AUC) of each insulin during the first hour after a standard meal.3 Faster absorption vs. Lispro regardless of weight4,a Vs lispro: Continue reading >>
What Is Apidra?
QUICK LINKS Insulin glulisine is a fast-acting type of insulin. Insulin is one of many hormones that help the body turn the food we eat into energy. This is done by using the glucose (sugar) in the blood as quick energy. Also, insulin helps us store energy that we can use later. When you have diabetes mellitus, your body cannot make enough insulin or does not use insulin properly. So, you must take additional insulin to regulate your blood sugar and keep your body healthy. This is very important as too much sugar in the blood can be harmful to your health. Insulin glulisine starts to work faster than some other types of insulin, and its effects do not last as long. It should act more like the insulin your body would normally produce. Because the effects of insulin glulisine are short-acting, your doctor may also prescribe a longer-acting insulin for you to use. This medicine is available only with your doctor's prescription. Find big savings at pharmacies near you with GoodRx discount coupons Lowest GoodRx Price $400.40 View All Prices A nurse or other trained health professional may give you this medicine. You may also be taught how to give your medicine at home. This medicine is given as a shot under your skin or into a vein. Always double-check both the concentration (strength) of your insulin and your dose. Concentration and dose are not the same. The dose is how many units of insulin you will use. The concentration tells how many units of insulin are in each milliliter (mL), such as 100 units/mL (U-100), but this does not mean you will use 100 units at a time. Each package of insulin glulisine contains a patient information leaflet. Read this leaflet carefully and make sure you understand: How to prepare the medicine. How to inject the medicine. How to use disposab Continue reading >>
Apidra Side Effects Center
Apidra (insulin glulisine [rdna origin] inj) is a hormone that is produced in the body used to treat diabetes in adults and children who are at least 4 years old. Apidra is usually given together with a long-acting insulin. Common side effects of Apidra include: injection site reactions (pain, redness, or irritation). Apidra can cause low blood sugar (hypoglycemia). Tell your doctor if you experience symptoms of low blood sugar including sudden sweating, shaking (tremor), fast heartbeat, hunger, blurred vision, dizziness, tingling hands/feet, headache, nausea, confusion, drowsiness, weakness, trouble concentrating, confusion, or seizure (convulsions). Tell your doctor if you have serious side effects of Apidra including: signs of low potassium level in the blood (such as muscle cramps, weakness, irregular heartbeat). The dosage of Apidra is individualized. Blood glucose monitoring is essential. The total daily insulin requirement may vary and is usually between 0.5 to 1 Unit/kg/day. Apidra may interact with albuterol, clonidine, guanethidine, lanreotide, niacin, octreotide pramlintide, reserpine, or beta-blockers. Many other medicines can increase or decrease the effects of Apidra on lowering your blood sugar. Tell your doctor all prescription and over-the-counter medications and supplements you use. Tell your doctor if you are pregnant before using Apidra. If you are planning pregnancy, discuss a plan for managing your blood sugars with your doctor before you become pregnant. Your doctor may switch the type of insulin you use during pregnancy. It is unknown if this drug passes into breast milk. Consult your doctor before breastfeeding. Our Apidra (insulin glulisine [rdna origin] inj) Side Effects Drug Center provides a comprehensive view of available drug information o Continue reading >>
Compare Apidra Vs. Humalog
Controls blood sugar. Apidra (insulin glulisine) is an insulin that controls blood sugar during your meals, but you'll still have to follow your doctor's diet and exercise plan. Apidra (insulin glulisine) starts working in as soon as 15 minutes. Programs are available to lower your copay. Talk to your doctor or pharmacist. Can be used in people over 65 and children 4 years of age and older. Humalog (insulin lispro) is the most effective medication for lowering your blood sugar. Humalog (insulin lispro) can be used even if you have liver or kidney problems, unlike other anti-diabetic medications. Not enough review data. 280 reviews so far Have you used Humalog (insulin lispro)? Leave a review Continue reading >>
Similarities And Differences Between Apidra Insuin Vs Humalog
Similarities and Differences Between Apidra Insuin vs Humalog Similarities and Differences Between Apidra Insuin vs Humalog Apidra and Humalog are both injectable insulins that are used to treat people with diabetes. These drugs help to reduce high blood sugar levels in people with type 1 and type 2 diabetes. Bothinsulin medications are fast-acting insulin analogs, meaning that they start to work quickly compared to other insulin analogs. However, there are differences between them, hence they cannot be used interchangeably. If your doctor prescribes either Apidra or Humalog, you may need to take them together with long-acting insulin. Apidra is a fast-acting insulin that has insulin glulisine . Insulin glulisine starts to work after 15 minutes and peaks after 1 hour. As a fast-acting insulin, it is recommended you take this medication 15 minutes before you eat, or 20 minutes after you eat. This medicine is only part of a treatment program which includes a diet plan, an exercise program, weight control and blood sugar testing. Your blood sugar will be affected in case you change any of these factors. It is used to treat adults with type 2 diabetes and type 1 diabetes in adults and children above the age of 4. However, the drug should not be taken by children younger than the age of 4. Humalog refers to another fast-acting insulin which is taken by people with diabetes to lower blood sugar levels. When injected under the skin, the medication starts to work after 15 minutes to lower your blood sugar levels. If you take this insulin drug with a meal, you should take it within 15 minutes before you eat or just after you take a meal. This medication should be used as it is prescribed by your doctor. Make sure you carefully follow the instructions on the prescription label. Continue reading >>
Apidra Side Effects
Generic Name: insulin glulisine (IN su lin GLOO lis een) Brand Names: Apidra What is Apidra? Apidra is an injection that contains insulin glulisine. Insulin is a hormone that works by lowering levels of glucose (sugar) in the blood. Insulin glulisine is a fast-acting insulin that starts to work about 15 minutes after injection, peaks in about 1 hour, and keeps working for 2 to 4 hours. Apidra is used to improve blood sugar control in adults and children with diabetes mellitus. Apidra is used to treat type 1 or type 2 diabetes in adults, and type 1 diabetes children who are at least 4 years old. Important information Apidra is a fast-acting insulin that begins to work very quickly. You should use it within 15 minutes before or 20 minutes after you start eating a meal. Never share an injection pen or syringe with another person, even if the needle has been changed. You should not use Apidra if you are having an episode of hypoglycemia (low blood sugar). Apidra is only part of a complete program of treatment that may also include diet, exercise, weight control, foot care, eye care, dental care, and testing your blood sugar. Follow your diet, medication, and exercise routines very closely. Changing any of these factors can affect your blood sugar levels. Before taking this medicine You should not use Apidra if you are allergic to insulin glulisine, or if you are having an episode of hypoglycemia (low blood sugar). Apidra is not approved for use by anyone younger than 4 years old, and should not be used to treat type 2 diabetes in a child of any age. To make sure Apidra is safe for you, tell your doctor if you have: liver or kidney disease; low levels of potassium in your blood (hypokalemia); or diabetic ketoacidosis (call your doctor for treatment). Tell your doctor if you Continue reading >>
What Is Rapid-acting Insulin?
Rapid-Acting insulins are insulin analogs that were developed to help imitate meal-induced insulin secretion. Many type 2 diabetes patients will eventually require bolus mealtime insulin to help achieve blood glucose control. Bolus mealtime insulin works quickly to lower the increase in blood sugar after eating. It does this by stimulating the cells in the body to absorb glucose from the bloodstream. They have a quick onset of action (15-20 minutes) and short duration of action (2-4 hours).* Rapid-acting insulin analogs are often used over regular insulin because of their quick onset, which allows patients to inject it closer to mealtime and because of their short duration, which decreases the risk of hypoglycemia (low blood sugar). Some of the rapid-acting insulins available in the US include: Apidra (insulin glulisine) is a rapid-acting insulin analog used in the treatment of type 2 diabetes.Apidra is given as a subcutaneous (under the skin) injection within 15 minutes before or within 20 minutes after starting a meal, but always consult with your healthcare provider on proper use. It can be injected in the abdomen, thigh, or shoulder. Injection sites should be rotated each time to prevent the risk of lipodystrophy, an accumulation of fatty tissue under the skin at the site where insulin is injected. Your healthcare provider will help determine your proper dose based on each individual’s specific needs and lifestyle. Apidra’s onset of action is 25 minutes and its effect lasts about 4-5 hours. Apidra can also be used in an insulin pump.1 People who are allergic to any of the ingredients in Apidra (insulin glulisine) should not take it. Always check with your healthcare professional about any potential drug interactions before starting treatment. Apidra is available Continue reading >>
Rapid Acting Mealtime Insulin |apidra (insulin Glulisine [rdna Origin] Injection)
insulin glulisine [rDNA origin] injection $10* COPAY FOR LANTUS FOR 12 MONTHS. Certain restrictions apply. Start saving & enroll now >> $10* COPAY FOR TOUJEO (insulin glargine injection 300 Units/mL) FOR 12 MONTHS. Certain restrictions apply. Start saving & enroll now >> One card. Savings for up to 12 diabetes medication fills. Certain restrictions apply. Start saving & enroll now >> Help your patients save on Apidra through our Mealtime Masters Program! Learn more >> Join a free webinar to learn about using Apidra (insulin glulisine [rDNA origin] injection) and making healthy choices with the Apidra COACH program. See Program Benefits >> Get tools and support for using Apidra (insulin glulisine [rDNA origin] injection) and making healthy mealtime choices when you join the free Apidra COACH program. See what youll receive >> (insulin glulisine [rDNA origin] injection) Apidra is a rapid-acting insulin analog indicated to improve glycemic control in adults with type 2 diabetes or adults and children (4 years and older) with type 1 diabetes. When used as a mealtime insulin, the dose of Apidra should be given within 15 minutes before or within 20 minutes after starting a meal. Apidra given by subcutaneous injection should normally be used in regimens that include a longer-acting insulin. Important Safety Information for Apidra (insulin glulisine [rDNA origin] injection) Apidra is contraindicated during episodes of hypoglycemia and in patients hypersensitive to Apidra or any of its excipients. Insulin pens, needles, or syringes must never be shared between patients. Do NOT reuse needles. Closely monitor blood glucose in all patients treated with insulin. Change insulin regimens cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, o Continue reading >>
